L
Lucy F. Chen
Researcher at Astellas Pharma
Publications - 4
Citations - 592
Lucy F. Chen is an academic researcher from Astellas Pharma. The author has contributed to research in topics: Enzalutamide & Androgen deprivation therapy. The author has an hindex of 2, co-authored 4 publications receiving 270 citations.
Papers
More filters
Journal ArticleDOI
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong,Russell Z. Szmulewitz,Daniel P. Petrylak,Jeffrey M. Holzbeierlein,Arnauld Villers,Arun Azad,Antonio Alcaraz,Boris Alekseev,Taro Iguchi,Neal D. Shore,Brad Rosbrook,Jennifer Sugg,Benoit Baron,Lucy F. Chen,Arnulf Stenzl +14 more
TL;DR: Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with mHSPC, including those with low-volume disease and/or prior docetaxel, with a safety analysis that seems consistent with the safety profile of enzalutamia in previous clinical trials in castration-resistant prostate cancer.
Journal ArticleDOI
Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
Andrew J. Armstrong,Russell Z. Szmulewitz,Daniel P. Petrylak,Arnauld Villers,Arun Azad,Antonio Alcaraz,Boris Alekseev,Taro Iguchi,Neal D. Shore,Brad Rosbrook,Jennifer Sugg,Benoit Baron,Lucy F. Chen,Arnulf Stenzl +13 more
TL;DR: ENZA + ADT significantly improved rPFS and other efficacy endpoints vs PBO +ADT in men with mHSPC, with a preliminary safety analysis that appears consistent with the safety profile of ENZA in previous CRPC clinical trials.
Journal ArticleDOI
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
Taro Iguchi,Go Kimura,Satoshi Fukasawa,Hiroyoshi Suzuki,Hiroji Uemura,Kazuo Nishimura,Hiroaki Matsumoto,Akira Yokomizo,Andrew J. Armstrong,Brad Rosbrook,Jennifer Sugg,Benoit Baron,Lucy F. Chen,Futoshi Kunieda,Arnulf Stenzl +14 more
TL;DR: In this article, the efficacy and safety of enzalutamide plus androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer was evaluated in the phase III, randomized, multinational ARCHES study (NCT02677896).
Journal ArticleDOI
ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
Andrew J. Armstrong,Russell Z. Szmulewitz,Daniel P. Petrylak,Jeffrey M. Holzbeierlein,Arnauld Villers,Arun Azad,Antonio Alcaraz,Boris Alekseev,Taro Iguchi,Neal D. Shore,Brad Rosbrook,Benoit Baron,Lucy F. Chen,Arnulf Stenzl +13 more
TL;DR: ENZA has demonstrated benefit in men with metastatic and nonmetastatic castration-resistant prostate cancer (CRPC) and ARCHES assessed the efficacy of ENZA with ADT inMen with mHSPC and found it to be equivalent to standard of care.